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In China, fosfomycin alone or in combination with other antibiotics is commonly used
in the treatment of infections caused by Gram-positive bacteria, including methicillin-
resistant Staphylococcus aureus (MRSA). Although fosfomycin-resistant S. aureus
strains have continued to emerge and increase, the research on them is rare. In order to
determine the prevalence and mechanisms of fosfomycin resistance in MRSA clinical
isolates, a total of 96 non-duplicate MRSA isolates were collected from blood and
cerebrospinal fluid samples at Huashan Hospital in Shanghai, China between 2004 and
2014. Antimicrobial susceptibility testing was performed by agar dilution. Meanwhile,
the fosfomycin-resistance-related genes, fosB, murA, glpT, and uhpT, were amplified
by PCR and subjected to sequencing analysis. Multilocus sequence typing (MLST)
was conducted to assess strain types. The minimum inhibitory concentration (MIC) of
fosfomycin for the 96 MRSA strains ranged from 1.0 to>1,024 mg/L, and approximately
70% (67/96) of the isolates were resistant to fosfomycin (MIC ≥ 64.0 mg/L). Nine isolates
with MICs ≥ 128 mg/L carried fosB gene. Twenty-five distinct mutations were detected
in the murA (7), glpT (10), and uhpT (8) genes. While five of the murA mutations and
five of the glpT mutations were observed only in fosfomycin-sensitive isolates and one
of the murA mutation was found both in fosfomycin-resistant and fosfomycin-sensitive
isolates, the remaining 14 mutations (1 murA, 5 glpT, and all uhpT mutations) were
present only in fosfomycin-resistant isolates. MLST analysis demonstrated that the
majority (46/67) of the glpT and/or uhpT mutants belong to ST5, the predominant
sequence type among the fosfomycin-resistant MRSA isolates. In conclusion, there is
a high rate of fosfomycin resistance in MRSA strains. The mutations in the murA, glpT,
and uhpT genes are common in fosfomycin-resistant MRSA strains, and may play a
greater role in the development of fosfomycin resistance than the presence of the fosB
gene in these organisms.
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INTRODUCTION
Methicillin-resistant Staphylococcus aureus (MRSA) is one of
the most common nosocomial pathogens, and resistant to most
β-lactam antibiotics and even new antimicrobials, which has
compelled clinicians to resort to some “old” antimicrobial agents
(DeLeo and Chambers, 2009). Fosfomycin, which was ﬁrst
discovered in Streptomyces sp. in 1969, possesses broad-spectrum
activity against both Gram-positive and Gram-negative bacteria
by inhibiting bacterial cell wall synthesis (Michalopoulos et al.,
2011). Speciﬁcally, fosfomycin deactivates the enzyme UDP-
N-acetylglucosamine-3-enolpyruvyltransferase, also known as
MurA (encoded by the murA gene), thereby irreversibly
interfering with the ﬁrst committed step of peptidoglycan
biosynthesis (Michalopoulos et al., 2011). In recent years, the
administration of fosfomycin alone or in combination with other
antibiotics has been prescribed for treatment of MRSA (Falagas
et al., 2009; Del Río et al., 2014; Sultan et al., 2015). However,
fosfomycin-resistant S. aureus strains have continued to emerge
and increase (Etienne et al., 1991). In China, the fosfomycin
resistance rate in MRSA was as high as 29.5% in 2010 (Guo et al.,
2013).
Bacterial fosfomycin resistance is attributed both to the
acquisition of chromosomal mutations and to the expression
of plasmid-encoded fosfomycin-modifying enzymes. Mutations
in murA have been shown to reduce the aﬃnity of fosfomycin
for MurA (Jiang et al., 2011). Additionally, fosfomycin intake
can be reduced in the presence of mutations in glpT and/or
uhpT, which encode fosfomycin transport systems of bacteria
(Takahata et al., 2010; Michalopoulos et al., 2011). Lastly,
fosfomycin activity can be inhibited via the catalytic activity
of FosA, FosB, FosC, and FosX, respectively (García et al.,
1995; Fillgrove et al., 2007; Lee et al., 2012). Meanwhile, of
the known plasmid-mediated fosfomycin resistance genes, only
fosB has been detected in Staphylococcus sp. To date, however,
most researches have focused on fosfomycin-resistant Gram-
negative bacteria, and relatively few studies have been conducted
in fosfomycin-resistant Gram-positive bacteria (Michalopoulos
et al., 2011). The purpose of this study was to investigate the
prevalence fosfomycin resistance and mutations in the murA,
glpT, and uhpT genes in fosfomycin-resistant MRSA strains
isolated in China.
MATERIALS AND METHODS
Bacterial Strains
A total of 96 MRSA clinical strains were isolated from
blood or cerebrospinal ﬂuid specimens at Huashan hospital,
a teaching hospital in Shanghai, China, between 2004 and
2014. S. aureus ATCC 29213 (American Type Tissue Culture
Collection, Manassas, VA, USA) was used as a quality control
strain in antimicrobial susceptibility testing experiments.
Antimicrobial Susceptibility Testing
The minimum inhibitory concentration (MIC) of fosfomycin
for each clinical strain was determined by agar dilution
supplemented with Glucose-6-phosphate (25 mg/L), according
to the recommendations of the Clinical and Laboratory
Standards Institute (Clinical and Laboratory Standards Institute
[CLSI], 2014), and results were interpreted according to
European committee on antimicrobial susceptibility testing
criteria (European Committee on Antimicrobial Susceptibility
Testing [EUCAST], 2012) (susceptible, ≤32 mg/L; resistant,
≥64 mg/L).
PCR Amplification
DNA of 96MRSA strains was harvested using TIANamp bacteria
DNA Kit (Tiangen, Beijing, China). The presence of the fosA,
fosB, and fosC, was detected by PCR as described previously
(Chen et al., 2014). murA, glpT and uhpT genes are ampliﬁed
by PCR using primers listed in Table 1. The PCR products were
sequenced to screen for mutations.
Multilocus Sequence Typing (MLST)
Staphylococcus aureus sequence types (STs) were determined by
comparing the sequences of the housekeeping genes arcC, aroE,
glp, gmk, pta, tpi, and yqiL, as described previously (Enright and
TABLE 1 | PCR primers of fosA, fosB, fosC, murA, glpT and uhpT gene.
Primers Gene Primer sequences (5′ > 3′) Product size Reference
fosA-F
fosA-R
fosA GCTGCACGCCCGCTGGAATA
CGACGCCCCCTCGCTTTTGT
217 bp Chen et al., 2014
fosB-F
fosB-R
fosB CAGAGATATTTTAGGGGCTGACA
CTCAATCTATCTTCTAAACTTCCTG
312 bp Chen et al., 2014
fosC-F
fosC-R
fosC GGGTTACATGCCCTTGCTCA
AACCCGCACAACGACAGATG
354 bp Chen et al., 2014
murA-F
murA-R
murA GCCCTTGAAAGAATGGTTCGT
GTTACAATACTCGACGCAGGT
1600 bp∗ NC_002745.2∗ ∗
glpT-F
glpT-R
glpT TGAATAAAACAGCAGGGCAA
CACAGCTAGTATGTATAACGAC
1699bp∗ NC_002745.2∗ ∗
uhpT-F
uhpT-R
uhpT TGTGTTTATGTTCAGTATTTTGGA
TCTTTCATCTCTTCACGCAC
1571 bp∗ NC_002745.2∗ ∗
∗PCR product including surrounding sequences adjacent to target gene.
∗∗GenBank-EMBL-DDBL accession number.
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Spratt, 1999), with those in the MLST database available at http://
saureus.mlst.net/ (Aanensen and Spratt, 2005).
Nucleotide Sequence Accession
Numbers
The sequences for the TypeAmurA, TypeImurA, TypeIImurA,
TypeIII–VImurA, TypeA–EglpT , TypeIglpT , TypeIIglpT , TypeIIIglpT ,
TypeVIglpT , TypeVglpT , and TypeA–HuhpT strains have been
deposited in GenBank with the following accession numbers:
KT372186, KT372187, KT372185, KT372188–KT372191,
KT372192–KT372196, KT372197, KT372198, KT372201,
KT372199, KT372200, and KT372202–KT372209, respectively.
RESULTS
Fosfomycin Susceptibility
The MICs of fosfomycin for the MRSA strains ranged from
1.0 mg/L to >1,024 mg/L. Furthermore, MIC50 and MIC90
values of these strains were 1,024 mg/L and >1,024 mg/L,
respectively. According to the EUCAST criteria, 67 out of the
96 examined MRSA isolates were characterized as fosfomycin-
resistant (MIC ≥ 64 mg/L).
Prevalence of Fosfomycin Resistance
Genes
Of the 96 MRSA isolates, 9 fosfomycin-resistant strains with
MIC ≥ 128 mg/L contained fosB (Table 2 and Supplementary
Table S1), and no isolates were positive for fosA and fosC.
Mutations in the murA Gene
Seven distinct mutations were detected in the murA gene of
the 96 MRSA isolates. Mutation TypeAmurA, which resulted in
the creation of a stop codon (TA125A) at position 42 and a
possible new start codon was found at position 94 (Figure 1), was
contained by one of the fosfomycin-resistant MRSA isolates. In
contrast, the other six mutations (TypeI–VImurA), which resulted
in distinct amino acid substitutions within the MurA protein,
could be found in fosfomycin-sensitive MRSA isolates, though
one mutation (TypeIImurA) also could be found in fosfomycin-
resistant MRSA isolates. (Table 3).
Mutations in glpT and uhpT Genes
Of the 67 fosfomycin-resistant MRSA isolates, 46 contained
one of the ﬁve diﬀerent mutations (TypeA–EglpT ) observed in
the glpT gene. While TypeEglpT resulted in an amino acid
substitution at position 137 (Trp-137→Arg) of GlpT, the other
four mutations produced premature stop codons within the glpT
coding sequence, thereby resulting in the generation of truncated
proteins (Figure 1). In addition, we detected ﬁve other mutations
within the glpT gene that were present only in the fosfomycin-
sensitive MRSA isolates. Each of these mutations (TypeI–VglpT )
resulted in amino acid substitutions within the GlpT protein
(Supplementary Table S2 and Table 4).
Eight distinct mutations were detected in the uhpT gene
(TypeA–HuhpT) of the fosfomycin-resistant MRSA isolates. TA
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FIGURE 1 | Types and positions of mutation in murA, glpT, and uhpT genes. TypeAmurA (KT372186): T125A (Result in a possible start codon in position 94th
aa); TypeImurA (KT372187): G193C; TypeIImurA (KT372185): G770A; TypeIIImurA (KT372188): C834A; TypeIVmurA (KT372189): A873T; TypeVmurA (KT372190):
A1085G; TypeVImurA (KT372191): CG1187-1188AT. TypeAglpT (KT372192): Deletion of 8bp from 225T to 232A; TypeBglpT (KT372193): G1064A; TypeC glpT
(KT372194): Deletion of 248G; TypeD glpT (KT372195): Insertion of 392T; TypeE glpT (KT372196): T409C; TypeIglpT (KT372197): T7A; TypeIIglpT (KT372198): C79T;
TypeIIIglpT (KT372201): C299T; TypeIVglpT (KT372199): G637A; TypeVglpT (KT372200): G1055A. TypeAuhpT (KT372202): Deletion of 27T; TypeBuhpT (KT372203):
Insertion of 904T; TypeCuhpT (KT372204): G1073T; TypeDuhpT (KT372205): G335A; TypeEuhpT (KT372206): Deletion of 12 bp from 431A to 442T; TypeFuhpT
(KT372207): G683A; TypeGuhpT (KT372208): C942A; TypeHuhpT (KT372209): T1273C.
Conversely, no uhpT mutations were detected in the fosfomycin-
sensitive isolates (Supplementary Table S3 and Table 4). The
TypeCuhpT , TypeDuhpT , and TypeHuhpT mutations led to amino
acid substitutions within the UhpT protein, while each of the
remaining mutations created premature stop codons within the
uhpT gene, resulting in the production of truncated protein
(Figure 1).
Molecular Typing
The 96 MRSA isolates were categorized into 11 ST types,
including ST5, ST6, ST30, ST59, ST88, ST121, ST239, ST398,
ST764, ST863, and ST2590 (Table 2). Notably, all ST5 strains and
45.7% (16/35) of the ST239 isolates were resistant to fosfomycin
(Supplementary Table S1 and Table 2).
DISCUSSION
The fosfomycin resistance rate of the MRSA isolates examined
in this study was approximately 70% (67/96), which was higher
than previously detected (Falagas et al., 2010). In consideration
of the average fosfomycin use was as high as 300,977 DDDs
(deﬁned daily doses) per year in Shanghai hospitals between
2009 and 2014 (Unpublished data), this elevated resistance
TABLE 3 | Characteristics of MRSA isolates containedmurA mutations.
Types of mutation Strain No. Mutations in murA∗ Fosfomycin MIC range (mg/L) fosB gene
TypeAmurA 1 T125A (Truncated to 41 aa) 1024 Negative
TypeImurA 1 G193C (Val 65 Leu) 2 Negative
TypeIImurA 29 G770A (Gly 257 Asp) 2 ∼ >1024 Negative
TypeIIImurA 2 C834A (Asp 278 Glu) 1 ∼ 2 Negative
TypeIVmurA 7 A873T (Glu 291 Asp) 1 ∼ 2 Negative
TypeVmurA 1 A1085G (Gln 362 Arg) 2 Negative
TypeVImurA 5 CG1187-1188AT (Thr 396 Asn) 1 ∼ 2 Negative
∗Deduced amino acid substitutions or sequence variations are shown in brackets.
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TABLE 4 | Characteristics of fosfomycin-resistant MRSA isolates contained glpT and uhpT mutations.
Mutation and its Combination Strain No. ST5 ST239 Other ST types
No. Fosfomycin
MIC range (mg/L)
No. Fosfomycin
MIC range (mg/L)
No. Fosfomycin
MIC range (mg/L)
TypeAglpT 5 2 1024 ∼ >1024 2 128 1 >1024
TypeAglpT and TypeAuhpT 1 0 – 0 – 1 >1024
TypeAglpT and TypeBuhpT 26 25 >1024 1 1024 0 –
TypeAglpT and TypeEuhpT 1 0 – 1 1024 0 –
TypeBglpT 2 2 64 0 – 0 –
TypeBglpT and TypeBuhpT 1 1 >1024 0 – 0 –
TypeBglpT and TypeCuhpT 5 5 1024 0 – 0 –
TypeBglpT and TypeFuhpT 1 1 >1024 0 – 0 –
TypeCglpT 1 1 512 0 – 0 –
TypeDglpT and TypeHuhpT 1 0 – 1 >1024 0 –
TypeEglpT and TypeCuhpT 1 0 – 1 >1024 0 –
TypeEglpT and TypeGuhpT 1 0 – 1 1024 0 –
TypeAuhpT 7 3 >1024 1 128 3 256 ∼ 512
TypeBuhpT 5 5 128 ∼ >1024 0 – 0 –
TypeCuhpT 1 1 1024 0 – 0 –
TypeDuhpT 1 0 – 1 >1024 0 –
rate may have been due to the common usage of this
antimicrobial in the region. However, while Etienne et al.
(1991) previously detected the fosB gene in 46% (18/39) of
fosfomycin-resistant S. aureus isolates, only 13.4% (9/67) of the
strains examined in this study harbored the fosB gene. Although
this gene was detected only in fosfomycin-resistant isolates,
the majority of such isolates were fosB-negative, indicating
that other mechanisms contribute to fosfomycin resistance in
S. aureus.
Sequencing analyses detected 25 distinct mutations in
the murA, glpT, and uhpT genes of the MRSA isolates
tested (Figure 1 and Supplementary Table S1). Of the
seven mutations present in murA, 6 (TypeI–VImurA) were
contained by fosfomycin-sensitive isolates, indicating that these
modiﬁcations did not confer fosfomycin resistance. Also,
while the TypeAmurA mutation was only detected in a single
fosfomycin-resistant isolate, this strain also harbored mutations
within glpT and uhpT. Thus, it is unclear what role, if any,
the TypeAmurA mutation plays in fosfomycin resistance in
MRSA.
Each of the uhpT mutations (TypeA–HuhpT) and ﬁve
of the glpT (TypeA–EglpT) mutations were present only
in fosfomycin-resistant isolates. Indeed, approximately
90% (60/67) of the fosfomycin-resistant strains harbored
a mutation in glpT and/or uhpT. Moreover, strains that
contained mutations in both glpT and uhpT exhibited high
levels of fosfomycin resistance (MIC > 1,024 mg/L; Table 2),
indicating that each of these 13 mutations might contribute
to fosfomycin resistance. In contrast, the remaining ﬁve
glpT mutations (TypeI–VglpT ), which were harbored only
by fosfomycin-sensitive strains, likely do not contribute to
fosfomycin resistance. Notably, several fosfomycin-resistant
isolates were fosB-negative, and did not harbor mutations in
murA, glpT, or uhpT. As such, the mechanism that governs
fosfomycin resistance in these isolates requires further
study.
Multilocus sequence typing analyses indicated that all of the
ST5 and 45.7% of the ST239 isolates were resistant to fosfomycin.
The majority of the glpT and/or uhpT mutants were typed as
ST5 (Table 2), and several strains harbored identical mutations
(Table 4), indicating that clonal dissemination may exist. The
ﬁrst ST5 strain emerged in 2004 (Supplementary Table S1).
The spread of this clone may be associated with the increased
occurrence of fosfomycin resistant MRSA. However, fosfomycin
resistance-associated mutations were also present in isolates
within other STs, suggesting that the emergence of fosfomycin
resistance is due to not only clonal dissemination, but also
fosfomycin selective pressure on isolates from diﬀerent clones,
and the emergence of spontaneous mutations.
CONCLUSION
We observed a high rate of fosfomycin resistance in MRSA
strains isolated from Shanghai, China. Our ﬁndings indicate
that mutations within the glpT and/or uhpT genes play
a critical role in conferring this resistance. Thus, the
continuous monitoring of fosfomycin susceptibility in S. aureus,
particularly in MRSA strains is important. Furthermore,
our results indicate that caution should be used when
employing fosfomycin for the empiric treatment of MRSA
infections.
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